Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hossam Nada

Showing results (21-30 of 79) with videos related to

Pageof 8
Sort By:
European Journal of Medicinal Chemistry|July 2, 2025
Lead optimization of a CHI3L1 inhibitor for Glioblastoma: Enhanced target engagement, pharmacokinetics, and efficacy in 3D spheroid modelsBaljit Kaur, Hossam Nada, Longfei Zhang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 20, 2025
Overcoming the undruggable barrier: Structure-guided discovery of a potent small molecule CD28 antagonist with translational potentialSaurabh Upadhyay, Hossam Nada, Sungwoo Cho, et al.
Journal of Medicinal Chemistry|November 21, 2025
Discovery of CD28-Targeted Small Molecule Inhibitors of T Cell Co-Stimulation Using Affinity Selection-Mass Spectrometry (AS-MS) and Ex Vivo ValidationSaurabh Upadhyay, Sungwoo Cho, Hossam Nada, et al.
European Journal of Medicinal Chemistry|July 15, 2025
CHI3L1-targeted small molecules as glioblastoma therapies: Virtual screening-based discovery, biophysical validation, pharmacokinetic profiling, and evaluation in glioblastoma spheroidsHossam Nada, Longfei Zhang, Baljit Kaur, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
CHI3L1-Targeted Small Molecules as Glioblastoma Therapies: Virtual Screening-Based Discovery, Biophysical Validation, Pharmacokinetic Profiling, and Evaluation in Glioblastoma SpheroidsHossam Nada, Longfei Zhang, Baljit Kaur, et al.
European Journal of Medicinal Chemistry|May 14, 2025
First-in-class dual inhibitors of MASTL and Aurora A kinase: Discovery of selective cyclohexa[b]thiophenes with potent anticancer activitySomaya A Abdel-Rahman, Hossam Nada, Moustafa T Gabr
Biorxiv : the Preprint Server for Biology|February 12, 2026
Exploiting NMR Ensemble Heterogeneity Enables Small Molecule Discovery Against Dynamic Protein-Protein InterfacesHossam Nada, Sungwoo Cho, Ashraf N Abdo, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Structure-Guided Optimization and Functional Characterization of Small Molecule Antagonists Targeting CD28 CostimulationSaurabh Upadhyay, Hossam Nada, Sungwoo Cho, et al.
Journal of Biomolecular Structure & Dynamics|January 13, 2023
Discovery and optimization of natural-based nanomolar c-Kit inhibitors via in silico and in vitro studiesHossam Nada, Sungdo Kim, Sreenivasulu Godesi, et al.
ACS Omega|November 17, 2025
Surface Plasmon Resonance (SPR)-Based Workflow for High-Throughput Discovery of CD28-Targeted Small MoleculesLaura Calvo-Barreiro, Hossam Nada, Saurabh Upadhyay, et al.
Pageof 8

Showing results (21-30 of 79) with videos related to

Sort By:
Pageof 8
European Journal of Medicinal Chemistry|July 2, 2025
Lead optimization of a CHI3L1 inhibitor for Glioblastoma: Enhanced target engagement, pharmacokinetics, and efficacy in 3D spheroid modelsBaljit Kaur, Hossam Nada, Longfei Zhang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 20, 2025
Overcoming the undruggable barrier: Structure-guided discovery of a potent small molecule CD28 antagonist with translational potentialSaurabh Upadhyay, Hossam Nada, Sungwoo Cho, et al.
Journal of Medicinal Chemistry|November 21, 2025
Discovery of CD28-Targeted Small Molecule Inhibitors of T Cell Co-Stimulation Using Affinity Selection-Mass Spectrometry (AS-MS) and Ex Vivo ValidationSaurabh Upadhyay, Sungwoo Cho, Hossam Nada, et al.
European Journal of Medicinal Chemistry|July 15, 2025
CHI3L1-targeted small molecules as glioblastoma therapies: Virtual screening-based discovery, biophysical validation, pharmacokinetic profiling, and evaluation in glioblastoma spheroidsHossam Nada, Longfei Zhang, Baljit Kaur, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
CHI3L1-Targeted Small Molecules as Glioblastoma Therapies: Virtual Screening-Based Discovery, Biophysical Validation, Pharmacokinetic Profiling, and Evaluation in Glioblastoma SpheroidsHossam Nada, Longfei Zhang, Baljit Kaur, et al.
European Journal of Medicinal Chemistry|May 14, 2025
First-in-class dual inhibitors of MASTL and Aurora A kinase: Discovery of selective cyclohexa[b]thiophenes with potent anticancer activitySomaya A Abdel-Rahman, Hossam Nada, Moustafa T Gabr
Biorxiv : the Preprint Server for Biology|February 12, 2026
Exploiting NMR Ensemble Heterogeneity Enables Small Molecule Discovery Against Dynamic Protein-Protein InterfacesHossam Nada, Sungwoo Cho, Ashraf N Abdo, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Structure-Guided Optimization and Functional Characterization of Small Molecule Antagonists Targeting CD28 CostimulationSaurabh Upadhyay, Hossam Nada, Sungwoo Cho, et al.
Journal of Biomolecular Structure & Dynamics|January 13, 2023
Discovery and optimization of natural-based nanomolar c-Kit inhibitors via in silico and in vitro studiesHossam Nada, Sungdo Kim, Sreenivasulu Godesi, et al.
ACS Omega|November 17, 2025
Surface Plasmon Resonance (SPR)-Based Workflow for High-Throughput Discovery of CD28-Targeted Small MoleculesLaura Calvo-Barreiro, Hossam Nada, Saurabh Upadhyay, et al.
Pageof 8